Human PD-L1 / B7-H1 / CD274 Protein 10084-HNAH from Sino Biological, Inc.

Product Specs
ItemHuman PD-L1 / B7-H1 / CD274 Protein
CompanySino Biological, Inc.
Price $348.00Supplier Page View Company Product Page
Catalog Number10084-HNAH
Size100 µg
Conjugate/TagUnconjugated
FormatLyophilized from sterile PBS, pH 7.4
Purity≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC
Activity1.Immobilized Recombinant Human PD-L1 / B7-H1 / CD274 Protein (Cat: 10084-HNAH) at 2 µg/mL (100 µL/well) can bind Anti-PD-L1 Antibody, Human IgG1 (Atezolizumab), the EC50 is 4-15 ng/mL.(QC tested). 2.Anti-PDL1 Antibody, Human IgG1 captured on Protein A chip can bind Recombinant Human PD-L1/B7-H1 Protein (Cat. No. 10084-HNAH) with an affinity constant of 8.81 nM as determined in an SPR assay (Biacore 8K) (Routinely tested). 3.Loaded Recombinant Human PD-1 Protein, hFc Tag (Cat. No. 10377-H02H) on AHC Biosensor, can bind Recombinant Human PD-L1/B7-H1 Protein (Cat. No. 10084-HNAH) with an affinity constant of 2.800 µM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested)
TypeRecombinant protein
Molecular WeightThe recombinant human CD274 consists of 220 amino acids and predicts a molecular mass of 25.2 kDa. As a result of glycosylation, the human CD274 migrates as an approximately 36 kDa protein in SDS-PAGE under reducing conditions
SpeciesHuman
Molecule NameCD274
Source/Expression SystemHEK293 Cells

Add to Compare List

Sino Biological, Inc.

37 Industrial Blvd

Suite B

Paoli, PA 19301

United States

Phone: 215-583-7898
Fax: 267-657-0217

Email: marketing@sinobiological.com

Company Profile

Website: sinobiological.com

(1) Nanofilament immunotherapy induces potent antitumor vaccine responsesJournal for immunotherapy of cancerAugust 31, 2025Neil K, Génier S, Poisson MÈ, Douchin J, Giguère H, Daniel L, Gonzalez MF, Huang S, Trinh VQ, Tai LH, et al.by phage, wells were coated with either 2 µg/mL of human PD-L1 recombinant protein (Sino Biological, 10084-HNAH) or mouse PD-L1 recombinant protein (Sino Biological, 50010-M08H). Nanofilament variants were diluted

(2) Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual ImmunotherapyJournal of medicinal chemistryJune 13, 2024Wang S, Kong Z, Shi Y, Shao C, Wang W, Su Z, Liu J, Zhou Y, Fei X, Cheng B, et al.

(3) PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapyFrontiers in immunologyJanuary 1, 2024Liang Y, Luo H, Li X, Liu S, Habib A, Liu B, Huang J, Wang J, Yi H, Hu B, et al.10377-RD67), recombinant human PD-L1 protein (Cat: 10084-H08H), human PD-L1/B7-H1/CD274 protein (Cat: 10084-HNAH), biotinylated mouse PD-1/PDCD1 protein (His tag) and recombinant human PD-1 protein (Cat: 10377-H08H)

(4) Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic AgentsJournal of medicinal chemistrySeptember 28, 2023Liu J, Cheng Y, Yuan L, Liu T, Ruan Y, Ren Y, Li L, Jiang S, Xiao Y, Chen J.

(5) Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer ImmunotherapyJournal of medicinal chemistryAugust 10, 2023Ding Z, Wang S, Shi Y, Fei X, Cheng B, Lu Y, Chen J.

(6) BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid TumorsAdvanced science (Weinheim, Baden-Wurttemberg, Germany)June 1, 2023Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI, Wu CC, Lin FY, Wang ST, Lin CY, et al.each well in a 96‐well plate was coated with 0.2 µg recombinant HLA‐G (TP305216, OriGene) or PD‐L1 (#10084‐HNAH, Sino Biological) protein at 4 °C overnight. After washing with phosphate‐buffered saline and Tween

(7) Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatmentBiochemical pharmacologyJune 1, 2021Cao H, Cheng B, Liu T, Chen J.

(8) Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer TreatmentJournal of medicinal chemistryDecember 24, 2020Cheng B, Wang W, Niu X, Ren Y, Liu T, Cao H, Wang S, Tu Y, Chen J, Liu S, et al.

Be the First to Write a Review!

Human PD-L1 / B7-H1 / CD274 Protein

Human PD-L1 / B7-H1 / CD274 Protein from Sino Biological, Inc.

Description

Sino Biological, Inc.

Citations (8)

Reviews

Human PD-L1 / B7-H1 / CD274 Protein from Sino Biological, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map